Comparative Pharmacology
Head-to-head clinical analysis: LENALIDOMIDE versus THALOMID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LENALIDOMIDE versus THALOMID.
LENALIDOMIDE vs THALOMID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.
Thalidomide is an immunomodulatory agent with antiangiogenic and anti-inflammatory properties. Its exact mechanism is not fully understood, but it inhibits tumor necrosis factor-alpha (TNF-α) production, modulates cytokine activity, and suppresses angiogenesis by inhibiting basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF).
10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.
200 mg orally once daily, taken with water preferably at bedtime to reduce sedation; dose may be titrated up to 400 mg daily based on tolerability.
None Documented
None Documented
Clinical Note
moderateLenalidomide + Digitoxin
"Lenalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLenalidomide + Deslanoside
"Lenalidomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLenalidomide + Acetyldigitoxin
"Lenalidomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateLenalidomide + Ouabain
"Lenalidomide may decrease the cardiotoxic activities of Ouabain."
Terminal half-life ~3 hours (range 2-5 h) in multiple myeloma patients; prolongation in renal impairment requires dose adjustment.
Mean terminal elimination half-life is approximately 5-7 hours in healthy adults; may be prolonged to 12-18 hours in patients with hepatic impairment due to decreased metabolism.
Renal: ~82% unchanged; fecal <5%; biliary negligible.
Primarily renal: >80% of absorbed dose excreted unchanged in urine. Minor fecal elimination (<15%). No significant biliary excretion.
Category C
Category C
Immunomodulatory Agent
Immunomodulatory Agent